Pharmacogenomics (PGx), is one of the most exciting areas of personalized medicine today. Pharmacogenomics helps to identify responders and non-responders to medications leading to potentially more appropriate treatment decisions, which can lead to less adverse events.
Patients typically respond to drugs differently and it can be difficult to predict who will benefit from a medication, who will not respond at all, and who will experience adverse effects. For certain drugs, researchers have identified genetic variations that influence how people respond and doctors can use the PGx to better understand a patient genetic make-up and accordingly select the best medication.

PGx has allowed for more tailored treatment of a wide range of health problems, including cardiovascular disease, cancer, and HIV/AIDS.


PGx360™ is a 22 genes, 62 genetic variations panel, designed to assist physicians in determining the most appropriate medications for their patients.  The genetic variants included in the panel are chosen based on the latest guidance from scientific groups like the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG), regulatory agency like the Federal Drug Administration (FDA) and the European Medicines Agency (EMA)

Genetic Panel

PGx360™ tests for genetic variants that can aid better prescription practices for more than 100 drugs in the following therapeutic areas:

  • Psychiatry and Addiction Medicine 
  • Pain Management
  • Neurology  
  • Cardiology/Vascular Diseases
  • Oncology 
  • Gastroenterology
  • Rheumatology
  • Urology 


FDA Table of Pharmacogenomic Biomarkers in Drug Labeling

PGx Gene-specific Information Tables

Implementation Resources for Pharmacogenomics

Pharmacogenomic Interpretation

The PGx360™ test results are interpreted and transformed in an actionable report for physician to discuss with their patients.